SCHEMBL6900571

SCHEMBL6900571

CCOC(=O)c1ccc(N(C)c2ccccc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.58
MEN1 O00255 2/20 0.58
SMN1; SMN2 Q16637 5/20 0.56
MAPT P10636 5/20 0.56
ALDH1A1 P00352 4/20 0.56
HPGD P15428 2/20 0.56
CA12 O43570 1/20 0.56
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
ESR1 P03372 1/20 0.56
CA7 P43166 1/20 0.56
CA9 Q16790 1/20 0.56
ESR2 Q92731 1/20 0.56
CA14 Q9ULX7 1/20 0.56
RAB9A P51151 5/20 0.55
NPC1 O15118 4/20 0.55
GAA P10253 1/20 0.55
LMNA P02545 3/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21784421 0.90 KMT2A (0.61) KMT2AMEN1SMN1; SMN2MAPTALDH1A1
SCHEMBL19187414 0.86 L3MBTL1 (0.56) KMT2AMEN1SMN1; SMN2MAPTALDH1A1
SCHEMBL4924913 0.85 MEN1 (0.60) KMT2AMEN1SMN1; SMN2MAPTALDH1A1
Ethyl Benzoate SCHEMBL27869298 0.85 ALDH1A1 (0.62) KMT2AMEN1SMN1; SMN2MAPTALDH1A1
SCHEMBL27403334 0.84 SMN1; SMN2 (0.50) KMT2AMEN1SMN1; SMN2MAPTALDH1A1
Ethyl Benzoate SCHEMBL21531031 0.84 LMNA (0.63) KMT2AMEN1SMN1; SMN2MAPTALDH1A1
Ethyl Benzoate SCHEMBL28029820 0.84 LMNA (0.68) KMT2AMEN1SMN1; SMN2MAPTALDH1A1
Benzene SCHEMBL27873122 0.84 CA1 (0.76) KMT2AMEN1SMN1; SMN2MAPTALDH1A1
Benzoyl Peroxide SCHEMBL32689642 0.83 ALDH1A1 (0.64) KMT2AMEN1SMN1; SMN2MAPTALDH1A1
Benzoic Acid SCHEMBL5190239 0.83 ALDH1A1 (0.64) KMT2AMEN1SMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3013787-B1 TRANSITION-METAL-FREE N-ARYLATION OF TERTIARY AMINES USING ARYNES COUNCIL SCIENT IND RES (IN) 2017-08-02 EP disclosed
EP-3013787-B1 TRANSITION-METAL-FREE N-ARYLATION OF TERTIARY AMINES USING ARYNES COUNCIL SCIENT IND RES (IN) 2017-08-02 EP disclosed
US-9650329-B2 Transition-metal-free N-arylation of tertiary amines using arynes COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-05-16 US disclosed
US-9650329-B2 Transition-metal-free N-arylation of tertiary amines using arynes COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2017-05-16 US disclosed
US-20160137587-A1 TRANSITION-METAL-FREE N-ARYLATION OF TERTIARY AMINES USING ARYNES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2016-05-19 US disclosed
US-20160137587-A1 TRANSITION-METAL-FREE N-ARYLATION OF TERTIARY AMINES USING ARYNES COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2016-05-19 US disclosed
EP-3013787-A1 TRANSITION-METAL-FREE N-ARYLATION OF TERTIARY AMINES USING ARYNES Council of Scientific & Industrial Research (IN) 2016-05-04 EP disclosed
WO-2014207761-A1 TRANSITION-METAL-FREE N-ARYLATION OF TERTIARY AMINES USING ARYNES COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2014-12-31 WO disclosed
EP-1100485-A4 SUBSTITUTED ANILIDE COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2004-06-09 EP disclosed
EP-1100485-A1 SUBSTITUTED ANILIDE COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2001-05-23 EP disclosed
WO-2000006146-A9 SUBSTITUTED ANILIDE COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2000-08-03 WO disclosed
WO-2000006146-A1 SUBSTITUTED ANILIDE COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2000-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160137587-A1 TRANSITION-METAL-FREE N-ARYLATION OF TERTIARY AMINES USING ARYNES CDK6, NEK6, MCM6 KMT2A 156/4885MEN1 3294/4885SMN1; SMN2 3941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.